Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
19.97 USD | -5.67% | -4.97% | -33.55% |
Apr. 15 | Intellia Therapeutics, Inc. Appoints Michael P. Dube as Principal Accounting Officer | CI |
Mar. 25 | Intellia Therapeutics Ends Development Agreement With Regeneron Pharmaceuticals | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-33.55% | 2.04B | |
+2.17% | 43.84B | |
+7.45% | 41.68B | |
+45.04% | 41.25B | |
-10.92% | 27.04B | |
+5.44% | 25.53B | |
-25.49% | 18.18B | |
-2.88% | 12.29B | |
+26.51% | 12.29B | |
+7.78% | 11.15B |
- Stock Market
- Equities
- NTLA Stock
- News Intellia Therapeutics, Inc.
- Intellia Therapeutics Expands Phase 1 Study of NTLA-2001 to Patients With Transthyretin Amyloidosis With Cardiomyopathy